A fog-lit field guide to the four-peptide KLOW research blend — KPV, GHK-Cu, BPC-157 and TB-500 traced arm by arm through the tissue-repair cascade, the mechanism read first and the missing blend data named for what it is.
Prescribed KLOW

DOSING RESEARCH · COMPONENT CONTEXT

What the component research administered — not a prescription for the KLOW blend

Four arms, four dose records, a pharmacokinetic mismatch built in — and no human dose for the blend itself.

Common questionsEffects and safety

Before the numbers

KLOW peptide dosage is a question the literature does not answer for the four-peptide blend. There is no controlled human or animal study that examined the KLOW combination and produced a dose-response curve. What exists is four separate dose records — one for each component — gathered in separate laboratories, using separate species and routes, for separate endpoints. None of those dose records automatically transfers to the blend. This page documents what the component research used, labeled by arm, so a reader understands the limits of what the literature supports.

KLOW peptide dosage — canonical vial composition

The most widely cited research-vial composition of KLOW is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. This composition appears across independent compounders as the canonical research formulation; no pharmacopeial or FDA-defined standard exists because KLOW is not an approved product. GHK-Cu's dominant share (~62.5% by mass) reflects its role as the matrix-remodeling and copper-delivery arm.

The four peptides do not have a single combined half-life. They clear at markedly different rates: the tripeptides KPV (MW 342.44 Da) and GHK-Cu (MW 402.92 Da) are small enough to clear faster than the larger BPC-157 (MW 1419.53 Da), which itself has a short half-life of under approximately 30 minutes in the one formal pharmacokinetic study; TB-500 (MW 889.02 Da) differs from native Tbeta4's profile. This pharmacokinetic mismatch means a single co-formulated dose will not hold all four components at matched plasma exposures simultaneously.

The blend is supplied lyophilized (freeze-dried) and reconstituted with bacteriostatic water for laboratory handling. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with the other peptides that has not been formally characterized.

KLOW dosage — what each arm was given in the literature

KPV doses in the research:

  • In vitro: 10 nM in human intestinal epithelial cell cultures (Caco2-BBE, HT29-Cl.19A); this nanomolar concentration was sufficient to inhibit NF-κB signaling [3].
  • In vivo (mice): 100 μM KPV administered in drinking water in C57BL/6 DSS- and TNBS-colitis models [3].
  • Delivery context: KPV-loaded mucoadhesive hydrogel and crosslinked polyglutamic-acid hydrogel delivery systems were developed to prolong exposure and enable local release [12][14].
  • Route in published studies: cell-culture medium (in vitro); oral / drinking water (in vivo); topical mucoadhesive (delivery studies).

GHK-Cu doses in the research:

  • In vitro: 1–10 nM concentration range for gene-expression and matrix-synthesis effects in fibroblast cultures [5].
  • Topical clinical: Formulation-specific; the comparative collagen-production trial used topical formulations and found effect at cosmetically feasible concentrations [4].
  • There are no systemic human dosing data for GHK-Cu; all human data are topical or cosmetic.

BPC-157 doses in the research:

  • Rodent tissue-repair: 10 μg/kg, 10 ng/kg and 10 pg/kg via intraperitoneal injection once daily in the Achilles-tendon transection model — three doses three orders of magnitude apart, all showing activity [2]. This dose-spanning behavior appears across the BPC-157 rodent literature.
  • Human safety pilot (2025): 10 mg on day 1, 20 mg on day 2, intravenous infusion in 250 cc saline over 1 hour in two adult volunteers; no adverse events observed [6]. A safety observation only.
  • Route in published studies: intraperitoneal; intravenous (human pilot); also locally administered in some rodent models.

TB-500 / thymosin beta-4 doses in the research:

  • Rat full-thickness wound model: Topical or intraperitoneal thymosin beta-4 at a concentration producing 10 pg-level migration stimulation in keratinocyte culture assays [1].
  • Note: Most published dose data are for native full-length Tbeta4 (43 amino acids). The TB-500 fragment (Ac-LKKTET-Q, 7 amino acids) has not been tested in a controlled dose-response study.
  • Route in published studies: topical; intraperitoneal.

None of these rodent or in-vitro doses constitute a human dosing recommendation for the KLOW blend or any of its components.

KLOW peptide dosage and frequency — what the literature studied

Dosing frequency in the BPC-157 rodent literature is once-daily intraperitoneal injection over multi-day recovery periods (the Achilles-tendon study spanned the recovery arc post-transection [2]). Thymosin beta-4 wound-model timing ran across 4- and 7-day post-wound assessments [1]. KPV studies measured effects at 24–72 hours in cell culture and over multi-week colitis models in mice [3]. GHK-Cu topical trials ran several weeks to months for skin endpoints [4].

Frequency of administration for the blend cannot be derived by averaging across these component protocols — the components are not interchangeable, their endpoints are different tissue processes, and the blend's pharmacokinetic mismatch means no single timing window is optimal for all four simultaneously.